



Positive Quality Intervention: Managing Myelofibrosis Patients

Description of PQI: Jakafi® (ruxolitinib) is a selective Jak2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy.

Background: Ruxolitinib is FDA approved for the treatment of intermediate or high-risk patients with MF. This includes patients with primary myelofibrosis, post PV MF, and post ET myelofibrosis.

PQI process: Pharmacy management of patients' labs to ensure correct dosing of ruxolitinib can contribute to increased efficacy and decreased toxicity of the therapy.

When receiving a new prescription for ruxolitinib:

- Review dosing
 - **Dosing of Ruxolitinib is based on baseline platelet count and platelet counts need to be monitored throughout therapy.**
 - Baseline dosing of ruxolitinib is as follows*:

Platelet Count	Ruxolitinib Dose
>200 x 10(9) cells/L	20 mg BID
100 to 200 x 10(9) cells/L	15 mg BID
50 to 99 x 10(9) cells/L	5mg BID

*Always assess pertinent drug-drug interactions and adjust dose accordingly

- Ensure that the patient has had a CBC, CMP, and lipid panel taken at baseline
- Ensure that the initial prescription is dosed properly
- Ensure the patient has follow up labs scheduled appropriately (see lab monitoring section)
 - Add reminder in pharmacy management software or EMR for follow up on patient's labs every 2-4 weeks until dose is stabilized (usually within 8 weeks)
- Refills will be filled only after:
 - CBC has been checked
 - Platelet count has been evaluated for appropriateness of dose

Important notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.



Pharmacy will evaluate platelet count and dose and may recommend the following dose adjustments to the prescribing physician:

Baseline Platelet Count of 100 x 10⁹ cells/L or Higher¹:

Current Platelet Count	Dose Adjustment
125 x 10 ⁹ cells/L or higher	No dose adjustment
100 to 124 x 10 ⁹ cells/L	If starting dose was 20mg BID, decrease dose by 5mg BID. If starting dose was 15mg BID or less, no adjustment needed
75 to 99 x 10 ⁹ cells/L	Decrease dose to 10mg BID If starting dose was 10mg BID or less, no adjustment needed
50 to 74 x 10 ⁹ cells/L	Decrease to 5mg BID If starting dose was 5mg BID, no adjustment needed
<50 x 10 ⁹ cells/L	Hold. May restart when Platelets >50 x 10 ⁹ cells/L

Baseline Platelet Count of 50 to 99 x 10⁹ cells/L¹:

Current Platelet Count	Dose Adjustment
25 to 35 x 10 ⁹ cells/L and platelet decline during prior 4 weeks is less than 20%	Decrease total daily dose by 5mg. For patients on 5mg once daily prior to decline, continue same dose
25 to 35 x 10 ⁹ and platelet decline during prior 4 weeks is 20% or higher	Decrease dose to 5mg BID If dose is 5mg BID, decrease to 5mg once daily If dose is 5mg once daily, continue same dose
<25 x 10 ⁹	Hold therapy. May restart when platelets >35 x 10 ⁹ cells/L starting with 5mg BID less than previous dose

Important notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.



Patient Centered Activities:

- Stress importance of adherence
 - The only way to achieve the proper patient-specific dose is if the patient is adherent to therapy
 - Schedule follow up calls
- Provide education:
 - Laboratory monitoring
 - Possibility of dose adjustments based on labs
- Monitoring Skin:
 - Important to notice all skin lesions
 - Examine skin at baseline
 - Make note of any new lesions that arise while on therapy

Dose Modifications:

- Dose adjust as noted above
- Do not adjust dose within the first 4 weeks, and no more than every 2 weeks thereafter
- Dose may be increased by 5mg BID increments to a max dose of 25mg BID if the patient meets the following:
 - Failure to achieve a reduction from baseline spleen length of 50% or a 35% reduction in spleen volume as measured by CT or MRI
 - Platelet count more than 125×10^9 cells/L at treatment week 4 and platelet counts never less than 100×10^9 cells/L
 - ANC more than 0.75×10^9 cells/L.
- Discontinue ruxolitinib if spleen size reduction or symptom improvement is not observed after 6 months of therapy
- When discontinuing therapy for any reason other than thrombocytopenia, consider gradually tapering dose by 5 mg twice daily each week

Lab Monitoring:

- CBC - baseline, every 2 to 4 weeks until dose is stabilized, then as clinically indicated
- Lipid panel - Baseline and 8 to 12 weeks after initiation
- Renal and hepatic function

References:

1. Jakafi (ruxolitinib) Package Insert. Accessed 12/2019. Revised 5/2019.

Important notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.